Amyotrophic Lateral Sclerosis Registry

Sponsor
yilong Wang (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05892822
Collaborator
(none)
1,000
1
18.6
53.9

Study Details

Study Description

Brief Summary

This study takes amyotrophic lateral sclerosis (ALS) patients as the main research object. Through collecting genetics, imaging and clinical symptoms for Exploratory research, we will construct the gene spectrum of ALS in China, explore unknown pathogenic genes, explore the characteristic image characteristics of ALS, and establish the iPSCs library of ALS, providing resources and basis for the research of pathogenesis and treatment targets of ALS.

Condition or Disease Intervention/Treatment Phase
  • Other: Amyotrophic Lateral Sclerosis

Detailed Description

This study is a multicenter, prospective registration study that will follow up patients with clinically confirmed and suspected amyotrophic lateral sclerosis for a period of 2 years. A total of 1000 patients will be included to dynamically observe the changes in clinical symptoms and signs, imaging, electrophysiology, biomarkers, biological samples and so on, which will construct a genetic profile of ALS in China, explore the etiology and pathogenesis, and establish an iPSCs library, provide a basis for finding treatment targets.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
1000 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Amyotrophic Lateral Sclerosis Registry
Anticipated Study Start Date :
Jun 15, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Amyotrophic Lateral Sclerosis

This study is an observational study without grouping.

Other: Amyotrophic Lateral Sclerosis
All ALS patients included in this group.

Outcome Measures

Primary Outcome Measures

  1. Gene Mutation Characteristics of ALS in Chinese [day 1]

    Constructing a Chinese ALS genetic information database by collecting genetic information from patients.

  2. The disease development of ALS in the Chinese [month 24]

    Record the progress of patients' clinical symptoms from baseline through 2-year follow-up.

Secondary Outcome Measures

  1. Exploring the imaging characteristics of ALS in the Chinese [day 1, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24]

    Record the change of the patient's head MRI from baseline through follow-up every 3 months.

  2. Establishing an iPSCs library for ALS in the Chinese [day 1]

    100 fALS and clinically typical sALS were selected. Monocytes were isolated from peripheral blood collected at baseline, and Reprogramming into iPSCs to establish iPSCs library.

  3. Analysis of the correlation between electrophysiology characteristics and imaging characteristics of ALS in Chinese [day 1, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24]

    Record the progression of the disease from an electrophysiological and imaging perspective by conducting electromyography and head MRI every 3 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years old ≤ age ≤ 80 years old;

  • Patients are diagnosed definite or probable ALS according to the Awaji diagnostic criteria;

  • Sign an informed consent form.

Exclusion Criteria:
  • Unable to cooperate with research or complete follow-up due to geographical or other reasons.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beijing Tiantan Hospital Beijing China 100050

Sponsors and Collaborators

  • yilong Wang

Investigators

  • Principal Investigator: Yilong Wang, M.D., Beijing Tiantan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
yilong Wang, Vice-President of Beijing Tiantan Hospital,Chief Scientist of Neurology Center, Beijing Tiantan Hospital
ClinicalTrials.gov Identifier:
NCT05892822
Other Study ID Numbers:
  • KY2023-013-02
First Posted:
Jun 7, 2023
Last Update Posted:
Jun 7, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by yilong Wang, Vice-President of Beijing Tiantan Hospital,Chief Scientist of Neurology Center, Beijing Tiantan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 7, 2023